Choosing event‐driven and daily HIV pre‐exposure prophylaxis – data from two European PrEP demonstration projects among men who have sex with men

Daily and event‐driven PrEP are both efficacious in reducing the risk for HIV infection. However, the practice of event‐driven PrEP (edPrEP) is less well studied, in particular when provided as an alternative to daily PrEP. We studied regimen preferences and switches, and sexually transmitted infection (STI) incidence.

[1]  A. Boyd,et al.  Understanding pre-exposure prophylaxis (PrEP) regimen use: Switching and discontinuing daily and event-driven PrEP among men who have sex with men , 2020, EClinicalMedicine.

[2]  F. V. Aar,et al.  Sexually transmitted infections in the Netherlands in 2019 , 2020 .

[3]  J. Volk,et al.  Early Adopters of Event-driven Human Immunodeficiency Virus Pre-exposure Prophylaxis in a Large Healthcare System in San Francisco. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  T. van der Poll,et al.  High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. , 2019, Journal of hepatology.

[5]  C. Delaugerre,et al.  On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. , 2019, The lancet. HIV.

[6]  B. Vuylsteke,et al.  Daily and event‐driven pre‐exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence , 2019, Journal of the International AIDS Society.

[7]  M. Prins,et al.  Motives for choosing, switching and stopping daily or event‐driven pre‐exposure prophylaxis – a qualitative analysis , 2019, Journal of the International AIDS Society.

[8]  A. Boyd,et al.  Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. , 2019, The lancet. HIV.

[9]  K. Ryan,et al.  Interest in Switching to On-Demand HIV Pre-Exposure Prophylaxis (PrEP) Among Australian Users of Daily PrEP: An Online Survey , 2019, Open forum infectious diseases.

[10]  Z. R. Greenwald,et al.  Cohort profile: l’Actuel Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada , 2019, BMJ Open.

[11]  M. Prins,et al.  A Mobile Application to Collect Daily Data on Preexposure Prophylaxis Adherence and Sexual Behavior Among Men Who Have Sex With Men: Use Over Time and Comparability With Conventional Data Collection , 2019, Sexually transmitted diseases.

[12]  B. Vuylsteke,et al.  Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project , 2018, Journal of acquired immune deficiency syndromes.

[13]  C. Delaugerre,et al.  Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. , 2018, AIDS.

[14]  L. Coyer,et al.  Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use: results from the Amsterdam pre-exposure prophylaxis demonstration project , 2018, AIDS.

[15]  T. Holtz,et al.  Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Hogewoning,et al.  Men who have sex with men more often chose daily than event‐driven use of pre‐exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam , 2018, Journal of the International AIDS Society.

[17]  C. Tremblay,et al.  Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up. , 2018, AIDS.

[18]  M. Boffito,et al.  InterPrEP: internet‐based pre‐exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London – analysis of pharmacokinetics, safety and outcomes , 2018, HIV medicine.

[19]  P. Reiss,et al.  Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. , 2017, The lancet. HIV.

[20]  M. Wainberg,et al.  Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. , 2017, The lancet. HIV.

[21]  A. Hogewoning,et al.  Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.

[22]  B. Vuylsteke,et al.  Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol , 2017, JMIR research protocols.

[23]  C. Boucher,et al.  Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.

[24]  R. Grant,et al.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations , 2016, AIDS.

[25]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[26]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[27]  C. Tremblay,et al.  Cost effectiveness of ‘on demand’ HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.